|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000117394 |
Summary for SLC2A1 |
Gene summary |
| Gene information | Ensembl ID | ENSG00000117394 | Gene symbol | SLC2A1 |
| Gene name | solute carrier family 2 member 1 | |
| HGNC | 11005 | |
| Entrez ID | 6513 | |
| Gene type | protein_coding | |
| Synonyms | SLC2A1|DYT18|DYT9|GLUT-1 | |
| UniProtAcc | P11166 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for SLC2A1 |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC2A1 | 5.04e+03 | -1.37e+00 | 2.05e-01 | -6.67e+00 | 2.58e-11 | 2.16e-09 | KIRP |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC2A1 | 4.62e+04 | 3.01e+00 | 5.56e-01 | 5.42e+00 | 6.09e-08 | 2.37e-06 | ESCA |
| SLC2A1 | 1.52e+03 | 3.20e+00 | 7.03e-01 | 4.56e+00 | 5.20e-06 | 3.15e-05 | CHOL |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC2A1 | 6.94e+03 | 1.49e+00 | 1.04e-01 | 1.44e+01 | 7.01e-47 | 6.42e-46 | BRCA |
| SLC2A1 | 1.12e+04 | 1.77e+00 | 4.54e-01 | 3.89e+00 | 9.99e-05 | 4.79e-04 | READ |
Top |
Sex-biased somatic mutation for SLC2A1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for SLC2A1 |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRP | cg05802386 | chr1:42957249 | CGI:chr1:42957796-42959097 | promoter,gene body | 6.69e-01 | 7.74e-01 | -2.79e+00 | 5.31e-03 | 1.44e-02 | -1.05e-01 |
| KIRP | cg20282814 | chr1:42957401 | CGI:chr1:42957796-42959097 | promoter,gene body | 6.84e-01 | 7.94e-01 | -3.17e+00 | 1.55e-03 | 6.52e-03 | -1.10e-01 |
| MESO | cg05802386 | chr1:42957249 | CGI:chr1:42957796-42959097 | promoter,gene body | 8.20e-01 | 7.04e-01 | 2.01e+00 | 4.46e-02 | 4.86e-02 | 1.16e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg05802386 | chr1:42957249 | CGI:chr1:42957796-42959097 | promoter,gene body | 3.65e-01 | 8.06e-01 | -4.47e+00 | 7.65e-06 | 5.26e-04 | -4.41e-01 |
| LUSC | cg20282814 | chr1:42957401 | CGI:chr1:42957796-42959097 | promoter,gene body | 4.47e-01 | 8.74e-01 | -4.45e+00 | 8.73e-06 | 5.26e-04 | -4.27e-01 |
| LUSC | cg12101479 | chr1:42960422 | CGI:chr1:42957796-42959097 | promoter | 7.83e-01 | 9.07e-01 | -3.64e+00 | 2.72e-04 | 1.15e-03 | -1.24e-01 |
| COAD | cg05802386 | chr1:42957249 | CGI:chr1:42957796-42959097 | promoter,gene body | 2.96e-01 | 3.96e-01 | -3.28e+00 | 1.05e-03 | 2.33e-03 | -1.00e-01 |
| BLCA | cg12101479 | chr1:42960422 | CGI:chr1:42957796-42959097 | promoter | 7.82e-01 | 9.03e-01 | -3.63e+00 | 2.79e-04 | 8.50e-04 | -1.21e-01 |
| LIHC | cg12101479 | chr1:42960422 | CGI:chr1:42957796-42959097 | promoter | 6.57e-01 | 8.47e-01 | -3.53e+00 | 4.08e-04 | 7.15e-04 | -1.91e-01 |
| KIRP | cg05802386 | chr1:42957249 | CGI:chr1:42957796-42959097 | promoter,gene body | 7.74e-01 | 6.17e-01 | 3.96e+00 | 7.52e-05 | 2.03e-04 | 1.57e-01 |
| KIRP | cg20282814 | chr1:42957401 | CGI:chr1:42957796-42959097 | promoter,gene body | 7.94e-01 | 6.51e-01 | 3.91e+00 | 9.14e-05 | 2.40e-04 | 1.44e-01 |
| CHOL | cg26188818 | chr1:42957976 | CGI:chr1:42957796-42959097 | promoter,gene body | 4.03e-02 | 2.64e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -2.24e-01 |
| CHOL | cg04287330 | chr1:42957925 | CGI:chr1:42957796-42959097 | promoter,gene body | 6.74e-02 | 2.50e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -1.82e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg05802386 | chr1:42957249 | CGI:chr1:42957796-42959097 | promoter,gene body | 4.14e-01 | 6.90e-01 | -1.24e+01 | 2.62e-35 | 8.13e-34 | -2.76e-01 |
| BRCA | cg20282814 | chr1:42957401 | CGI:chr1:42957796-42959097 | promoter,gene body | 4.50e-01 | 7.08e-01 | -1.16e+01 | 4.00e-31 | 6.71e-30 | -2.58e-01 |
| KIRC | cg20282814 | chr1:42957401 | CGI:chr1:42957796-42959097 | promoter,gene body | 5.12e-01 | 3.86e-01 | 2.28e+00 | 2.27e-02 | 2.93e-02 | 1.27e-01 |
Top |
Exon skipping events with PSI in TCGA for SLC2A1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for SLC2A1 |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for SLC2A1 |
TFs related to SLC2A1.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MESO | ZNF418 | SLC2A1 | 1.06e+00 | 2.22e-05 | 3.93e+00 | 9.84e-01 | Female-biased |
SLC2A1 related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for SLC2A1 |
RBPs related to ES in SLC2A1.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| STAD | SAMD4A | exon_skip_25685 | 6.65e+00 | 9.81e-01 | 6.16e+00 | 2.92e-03 | Male-biased |
| UVM | IGF2BP2 | exon_skip_25677 | 7.99e+00 | 8.74e-03 | 8.30e+00 | 9.84e-01 | Female-biased |
| UVM | IGF2BP3 | exon_skip_25677 | 7.99e+00 | 8.67e-03 | 8.30e+00 | 9.84e-01 | Female-biased |
| THYM | SRSF7 | exon_skip_25678 | 9.63e+00 | 3.24e-03 | 1.00e+01 | 9.95e-01 | Female-biased |
| LUSC | SAMD4A | exon_skip_25678 | 7.22e+00 | 9.85e-01 | 6.70e+00 | 2.86e-03 | Male-biased |
| COAD | SAMD4A | exon_skip_25678 | 6.17e+00 | 1.43e-04 | 6.99e+00 | 9.86e-01 | Female-biased |
| KIRP | SRSF7 | exon_skip_25678 | 9.60e+00 | 9.48e-03 | 9.94e+00 | 9.88e-01 | Female-biased |
| BRCA | SAMD4A | exon_skip_25678 | 6.47e+00 | 7.29e-03 | 7.19e+00 | 9.80e-01 | Female-biased |
| THCA | SAMD4A | exon_skip_25678 | 6.83e+00 | 9.83e-01 | 6.41e+00 | 1.80e-03 | Male-biased |
| THCA | SRSF7 | exon_skip_25678 | 9.43e+00 | 1.61e-03 | 9.88e+00 | 9.96e-01 | Female-biased |
| MESO | SRSF7 | exon_skip_25678 | 9.76e+00 | 1.45e-02 | 1.01e+01 | 9.84e-01 | Female-biased |
| LGG | SAMD4A | exon_skip_25678 | 7.01e+00 | 9.86e-01 | 6.24e+00 | 1.82e-04 | Male-biased |
| KIRC | SAMD4A | exon_skip_25678 | 6.41e+00 | 1.92e-05 | 7.38e+00 | 9.89e-01 | Female-biased |
| KICH | SRSF7 | exon_skip_25678 | 9.78e+00 | 9.95e-01 | 9.35e+00 | 3.12e-03 | Male-biased |
| SARC | SAMD4A | exon_skip_25678 | 6.68e+00 | 4.80e-03 | 7.12e+00 | 9.82e-01 | Female-biased |
SLC2A1 related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11210595 | chr1:42122325:C:A | - | 0.0691048101383395 | 0.0334577982285881 | LGG | Female-baised eQTL |
| rs11210596 | chr1:42122656:T:C | - | 0.0691048101383395 | 0.0334577982285881 | LGG | Female-baised eQTL |
| rs1889127 | chr1:42113116:C:T | - | 0.066628069790813 | 0.0459695261055728 | LGG | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11264006 | chr1:37260296:C:G | - | 0.221626508396427 | 0.000106515343837495 | SARC | Male-baised eQTL |
| rs72686073 | chr1:44280545:G:A | - | 0.134321046158616 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs41270415 | chr1:44219992:C:T | - | 0.129356661535692 | 0.00703406372611405 | SARC | Male-baised eQTL |
| rs3845493 | chr1:37092075:C:A | - | 0.186903298914202 | 0.0073872038379844 | SARC | Male-baised eQTL |
| rs4652936 | chr1:37092200:G:A | - | 0.186903298914202 | 0.0073872038379844 | SARC | Male-baised eQTL |
| rs7539225 | chr1:41647852:A:G | - | 0.122279454067749 | 0.0398481229091728 | SARC | Male-baised eQTL |
| rs7541822 | chr1:41648022:T:C | - | 0.122279454067749 | 0.0398481229091728 | SARC | Male-baised eQTL |
| rs6699235 | chr1:41651774:A:T | - | 0.122279454067749 | 0.0398481229091728 | SARC | Male-baised eQTL |
| rs78410207 | chr1:41646956:A:G | - | 0.12209014217722 | 0.0408345599221373 | SARC | Male-baised eQTL |
| rs28684469 | chr1:41646520:G:A | - | 0.121946830009843 | 0.0417883617708898 | SARC | Male-baised eQTL |
| rs7535727 | chr1:48640618:G:T | - | 0.0794737592439594 | 0.0282333671287199 | BLCA | Male-baised eQTL |
| rs78645362 | chr1:48641687:A:G | - | 0.0764245214969079 | 0.0383036950563118 | BLCA | Male-baised eQTL |
| rs72653591 | chr1:37112530:C:T | - | 0.0534268516611035 | 0.0388903834356923 | BLCA | Male-baised eQTL |
| rs66626960 | chr1:37111819:C:T | - | 0.0515176899278646 | 0.0409892136052398 | BLCA | Male-baised eQTL |
| rs113087909 | chr1:32966260:T:C | - | 0.0619954793529162 | 0.0421717268885757 | BLCA | Male-baised eQTL |
| rs12058997 | chr1:48642154:T:C | - | 0.0755388068997488 | 0.0433445538045455 | BLCA | Male-baised eQTL |
| rs12121968 | chr1:43881422:T:C | - | 0.11202848888106 | 0.026620833388594 | LUAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg20294984 | chr1:42947081 | gene | -0.434397980085227 | 1.47459920300325e-10 | -0.5510728881028059 | 1.194596106629555e-14 | COAD |
| cg15089806 | chr1:42952528 | gene | -0.434397980085227 | 1.47459920300325e-10 | -0.5510728881028059 | 1.194596106629555e-14 | COAD |
| cg22025263 | chr1:42953804 | gene | -0.434397980085227 | 1.47459920300325e-10 | -0.5510728881028059 | 1.194596106629555e-14 | COAD |
| cg01924561 | chr1:42950432 | gene | -0.302552493953019 | 5.25998923840328e-10 | -0.5227332519830781 | 4.2840968892139837e-13 | COAD |
| cg00737593 | chr1:42956666 | gene | -0.302552493953019 | 5.25998923840328e-10 | -0.5227332519830781 | 4.2840968892139837e-13 | COAD |
| cg22025263 | chr1:42953804 | gene | -0.489343652543117 | 1.08832141466371e-51 | -0.8355997304147917 | 1.140910334395682e-53 | KIRP |
| cg01924561 | chr1:42950432 | gene | -0.480606116630326 | 5.60336550243847e-28 | -0.647430482151663 | 1.8907695962875325e-31 | LIHC |
| cg09502149 | chr1:42941121 | gene | -0.227308248451405 | 5.50162751120235e-10 | -0.44057834446943556 | 1.9428854042938896e-13 | LIHC |
| cg20282814 | chr1:42957401 | gene,promoter | -0.227308248451405 | 5.50162751120235e-10 | -0.44057834446943556 | 1.9428854042938896e-13 | LIHC |
| cg01924561 | chr1:42950432 | gene | -0.43145197767196 | 2.11776439775625e-15 | -0.47692492090234256 | 8.055248959041847e-18 | LGG |
| cg05802386 | chr1:42957249 | gene,promoter | -0.43145197767196 | 2.11776439775625e-15 | -0.47692492090234256 | 8.055248959041847e-18 | LGG |
| cg05942022 | chr1:42936920 | gene | -0.207343056748781 | 1.02793025303486e-06 | -0.32848531878834514 | 1.3510897387722229e-08 | LGG |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of SLC2A1 |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000117394 | SLC2A1 | C0004134 | Ataxia | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0007102 | Malignant tumor of colon | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0007124 | Noninfiltrating Intraductal Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0008073 | Developmental Disabilities | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0009375 | Colonic Neoplasms | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0020796 | Profound Mental Retardation | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0022333 | Jacksonian Seizure | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0023903 | Liver neoplasms | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0025521 | Inborn Errors of Metabolism | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0025958 | Microcephaly | 2 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0027765 | nervous system disorder | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0029408 | Degenerative polyarthritis | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0031149 | Peritoneal Neoplasms | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0036572 | Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0085996 | Child Development Deviations | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0085997 | Child Development Disorders, Specific | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0086743 | Osteoarthrosis Deformans | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0149958 | Complex partial seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0234533 | Generalized seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0234535 | Clonic Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0240991 | Ataxia, Sensory | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0270824 | Visual seizure | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0270844 | Tonic Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0270846 | Epileptic drop attack | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0278161 | Ataxia, Motor | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0346990 | Carcinomatosis of peritoneal cavity | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0422850 | Seizures, Somatosensory | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0422852 | Seizures, Auditory | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0422853 | Olfactory seizure | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0422854 | Gustatory seizure | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0422855 | Vertiginous seizure | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0427190 | Ataxia, Truncal | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0494475 | Tonic - clonic seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0520966 | Abnormal coordination | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0750937 | Ataxia, Appendicular | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0750940 | Tremor, Rubral | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0751056 | Non-epileptic convulsion | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0751110 | Single Seizure | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0751123 | Atonic Absence Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0751494 | Convulsive Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0751495 | Seizures, Focal | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0751496 | Seizures, Sensory | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0917816 | Mental deficiency | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C0919267 | ovarian neoplasm | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1176475 | Ductal Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1332347 | Atypical Ductal Breast Hyperplasia | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1832855 | CHOREOATHETOSIS/SPASTICITY, EPISODIC | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1837206 | Cryohydrocytosis, Stomatin-Deficient, with Mental Retardation, Seizures, Cataracts, and Massive Hepatosplenomegaly | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1842534 | DYSTONIA 18 (disorder) | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1847501 | Glut1 Deficiency Syndrome | 4 | CTD_human |
| ENSG00000117394 | SLC2A1 | C1956147 | Microlissencephaly | 2 | CTD_human |
| ENSG00000117394 | SLC2A1 | C2239176 | Liver carcinoma | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C3495874 | Nonepileptic Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C3714756 | Intellectual Disability | 1 | CTD_human |
| ENSG00000117394 | SLC2A1 | C3853041 | Severe Congenital Microcephaly | 2 | CTD_human |
| ENSG00000117394 | SLC2A1 | C4048158 | Convulsions | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C4316903 | Absence Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C4317109 | Epileptic Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C4317123 | Myoclonic Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C4505436 | Generalized Absence Seizures | 3 | CTD_human |
| ENSG00000117394 | SLC2A1 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |